HealthEquity (HQY)
(Delayed Data from NSDQ)
$83.09 USD
+4.91 (6.28%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $83.11 +0.02 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.09 USD
+4.91 (6.28%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $83.11 +0.02 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
Zacks News
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong global expansion.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.
Here's Why Investors Should Invest in Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
by Zacks Equity Research
QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.
Reasons to Retain Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024
by Zacks Equity Research
HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.
3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical
by Zacks Equity Research
Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
Hologic (HOLX) to Boost Breast Imaging Modality With New Pact
by Zacks Equity Research
Hologic's (HOLX) collaboration with Bayer will enable physicians everywhere to include CEM in their breast cancer diagnosis workflows.
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Walgreens (WBA) New Study Shows Medical Adherence Importance
by Zacks Equity Research
Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.
3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
DexCom (DXCM) Launches Latest CGM Sensor ONE in France
by Zacks Equity Research
DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.